Applying biotechnology to overcome cancer drug resistance and improve public health outcomes

Abstract

This review examines how biotechnology advances (CRISPR/Cas9, next-generation targeted therapies, nanotechnology-based drug delivery, and immunotherapies) can be applied to address cancer drug resistance worldwide. It also considers the economic burden of resistance, inequities in access to biotechnology solutions, and ethical concerns surrounding rapid innovation, particularly in low-resource settings. A narrative review synthesized evidence from basic science studies, clinical trials, translational research, and policy analyses. Evidence was prioritized for 2015–2025 publications. The synthesis highlights resistance biology and evaluates how precision medicine, biomarker-guided treatment, and high-throughput drug screening can inform individualized regimens and rational combinations. Breakthroughs in gene editing, targeted inhibitors, nanocarriers, and immune engineering can counter key resistance mechanisms, including resistance-conferring mutations, altered drug transport, immune evasion, and tumor microenvironment–mediated protection. Despite progress, implementation barriers remain substantial: high drug and development costs, limited molecular diagnostics and manufacturing capacity, and regulatory and governance challenges that can delay adoption and widen disparities, particularly in low- and middle-income countries. Integrating biotechnology innovations within precision medicine frameworks may improve treatment selection and patient outcomes. Maximizing public health impact requires affordability and financing strategies, robust ethical oversight, timely regulatory pathways, and coordinated global collaboration to ensure access to effective therapies across health systems worldwide.

Graphical abstract

Introduction

Overview of Cancer and Drug Resistance

Cancer is associated with substantial morbidity and mortality worldwide [1]. It is the second leading cause of death globally, and its overall burden is projected to increase over the next 20 years [2]. Approximately 20 million new cancer cases were reported in 2022 [3]. In addition to being a major barrier to increasing life expectancy, cancer imposes significant societal and macroeconomic costs that vary according to cancer type, geographic region, and gender [4]. Despite advances in cancer treatment, including chemotherapy, radiation therapy, and targeted therapies, cancer remains a major global health burden. Conventional treatment approaches such as surgery, chemotherapy, and radiation have improved survival rates for many patients, but their effectiveness is frequently limited by the ability of cancer cells to develop resistance to these interventions [5]. As a result, treatments may fail, leading to poor survival outcomes [6].

Cancer drug resistance occurs when cancer cells fail to respond to a drug that was initially effective in treating the disease [7]. This resistance can be intrinsic, meaning that tumor cells are inherently resistant to therapy from the outset, or acquired, meaning that cancer cells develop resistance following an initial response to treatment [8]. Drug resistance is particularly relevant in the context of chemotherapy, where the emergence of resistance frequently leads to tumor recurrence, disease progression, and a poor prognosis for patients [9].

The mechanisms underlying cancer drug resistance are complex and include genetic mutations, alterations in drug transport systems, changes in intracellular signaling pathways, and evasion of immune surveillance [10,11]. As cancer cells evolve, they adapt to sustained therapeutic pressures, progressively reducing the effectiveness of standard treatments [12]. Consequently, overcoming cancer drug resistance remains a major and persistent challenge in oncology.

Biotechnology plays a vital role in the development of innovative therapeutic strategies to overcome cancer drug resistance. Substantial advances in genetic engineering, molecular biology, nanotechnology, and related biotechnological fields have generated new tools to target resistance mechanisms and enhance the efficacy of cancer treatments [12].

This paper aims to explore recent biotechnological approaches to cancer drug resistance by examining the mechanisms that drive resistance, emerging therapeutic innovations, and the public health challenges associated with implementing these solutions globally. In addition, it examines the role of biotechnology in improving cancer treatment outcomes while emphasizing the importance of ensuring equitable access to advanced therapies across populations, regardless of socioeconomic status.

Research Methodology

The study employed a narrative review approach to examine the role of biotechnology in overcoming cancer drug resistance. This approach was selected because it allows for a flexible and integrative synthesis of heterogeneous evidence, including basic science studies, clinical trials, translational research, and policy analyses, thereby facilitating the development of a coherent account of technological advances, biological mechanisms, and public health implications. The review design emphasized breadth and interpretive depth rather than formal meta-analytic aggregation, which was appropriate given the rapidly evolving and multidisciplinary nature of the topic.

Search Terms and Strategy

Data for the review were gathered through an iterative literature search of peer-reviewed journals, clinical reports, and relevant gray literature. Major bibliographic databases, including PubMed, Scopus, Web of Science, and Google Scholar, were searched using combinations of terms such as “cancer drug resistance,” “biotechnology,” “CRISPR,” “nanomedicine,” “epigenetic modulators,” “immunotherapy,” and “AI in oncology.” The search strategy prioritized recent publications (2015–2025) to capture contemporary biotechnological innovations, while also incorporating seminal earlier studies that elucidated foundational mechanisms. Inclusion criteria required that sources be peer-reviewed and address mechanisms of resistance, biotechnological interventions, clinical applications, or issues related to implementation and equity; editorials and commentaries were included selectively when they provided relevant conceptual or policy insight. Research articles that did not engage with drug-resistance mechanisms or biotechnological solutions, as well as items lacking sufficient methodological or evidentiary detail, were excluded.

Data Synthesis and Analysis

The extracted material described mechanistic features such as intrinsic and acquired resistance, multidrug resistance (MDR), and contributions from the tumor microenvironment (TME). It also encompassed biotechnological strategies, including gene-editing approaches, targeted therapies, immunotherapies, nanotechnology-based delivery systems, and epigenetic modulators. The review further incorporated reports of clinical applications and examined implementation challenges, including cost, access, regulatory barriers, and ethical considerations. Information was systematically recorded in a study log documenting bibliographic details, study objectives, methods, key findings, limitations, and relevance to the review question. The collected literature was coded for recurring concepts and patterns related to mechanisms of resistance, technological strategies to counter resistance, therapeutic combinations and sequencing, biomarkers, precision medicine approaches, and system-level barriers to adoption. These codes were subsequently organized into higher-order themes that structured the narrative: (1) biological bases of resistance, (2) molecular and delivery-focused biotechnological solutions, (3) clinical and translational evidence for efficacy, and (4) public-health, ethical, and regulatory implications.

The study maintained ethical and methodological rigor by applying transparent inclusion criteria, documenting search processes and analytical decisions in a review log, and critically evaluating the strength of evidence when drawing conclusions. Because the review relied exclusively on secondary, publicly available sources, no formal institutional review board approval was required; nevertheless, the work adhered to established academic standards for appropriate attribution, balanced interpretation, and clear discussion of ethical issues.

Mechanisms of Cancer Drug Resistance

Intrinsic Drug Resistance

Intrinsic resistance refers to the inherent ability of certain cancer cells to resist the effects of chemotherapy or targeted therapies from the outset of treatment [13]. This form of resistance can be attributed to several factors, including the underlying genetic and molecular characteristics of tumor cells [14]. Tumor heterogeneity, in which distinct cell populations within the same tumor harbor different genetic mutations, can contribute to intrinsic resistance [15]. Cancer cells may already possess mutations that reduce their susceptibility to chemotherapeutic agents [16]. In some cases, these cells exhibit enhanced drug-metabolizing pathways that allow them to inactivate or neutralize therapeutic agents before the drugs can exert their intended effects. Additionally, tumor cells frequently display altered drug uptake and efflux mechanisms [17]. The expression of drug transporters, such as P-glycoprotein, can actively pump chemotherapeutic agents out of the cell, thereby preventing adequate intracellular drug accumulation [17]. This represents another important mechanism by which intrinsic drug resistance can arise.

Apoptosis is a form of programmed cell death that enables the orderly elimination of damaged or unnecessary cells, including those affected by DNA damage or developmental cues [18]. Alterations in the apoptotic machinery can allow cancer cells to evade destruction, even in the presence of drugs that would normally induce cell death in non-malignant cells [19].

Acquired Drug Resistance

Acquired resistance occurs when cancer cells that are initially sensitive to therapy gradually become resistant over time. This form of resistance develops through a combination of genetic mutations and adaptive cellular changes that enable tumor cells to evade the effects of anticancer drugs. Acquired resistance can arise through multiple mechanisms, including mutations in drug target proteins, activation of alternative signaling pathways, and enhanced DNA repair capacity [5]. One example involves tyrosine kinase inhibitors, which are used in cancers such as chronic myelogenous leukemia. Acquired mutations in the BCR-ABL gene can render these drugs ineffective [20]. Similarly, mutations in the epidermal growth factor receptor (EGFR) can lead to resistance to EGFR inhibitors in non-small cell lung cancer [21].

Acquired resistance poses a major challenge in cancer treatment because it frequently leads to therapeutic failure, and patients who initially respond to therapy may later experience tumor recurrence [22]. The emergence of acquired resistance in clinical settings underscores the need for continuous monitoring and the ongoing development of new therapeutic strategies to address this evolving problem [23].

Multidrug Resistance

MDR is a complex form of resistance in which cancer cells become resistant to multiple chemotherapy agents, thereby reducing the effectiveness of standard treatment regimens [24]. MDR primarily arises from the overexpression of drug efflux pumps, such as P-glycoprotein and MDR–associated protein [25]. These transporters actively expel a wide range of chemotherapeutic agents from cancer cells, rendering treatments less effective [26]. This form of resistance is frequently observed in cancers that have undergone repeated cycles of chemotherapy, during which tumor cells are exposed to multiple drugs over time. As a result, MDR substantially limits the number of viable treatment options available to patients. Overcoming this form of resistance therefore requires the development of strategies that either inhibit drug efflux pumps or employ alternative mechanisms of drug delivery [24].

Impact of the Tumor Microenvironment

The TME plays a critical role in the development and persistence of cancer drug resistance [26]. The TME comprises multiple components, including cancer-associated fibroblasts, immune cells, blood vessels, and extracellular matrix elements [27]. Together, these components create a protective niche that shields cancer cells from therapeutic agents. For example, hypoxic conditions within solid tumors can promote resistance by inducing the expression of genes that protect cancer cells from chemotherapy-induced damage [28]. Tumors characterized by low oxygen tension frequently exhibit enhanced DNA repair capacity, increased drug resistance, and reduced susceptibility to apoptosis [28]. In addition, the immunosuppressive nature of the TME contributes to resistance by limiting effective immune surveillance and immune-mediated elimination of cancer cells [29]. Certain populations of tumor-associated macrophages can further protect cancer cells from drug-induced cytotoxicity by secreting a range of bioactive factors [30]. These factors may include enzymes, exosomes, interleukins, and chemokines, all of which can contribute to the development and maintenance of drug resistance [31].

Moreover, the extracellular matrix and stromal cells can form physical barriers that impede drug penetration into tumor tissue [26]. This results in an environment in which cancer cells are less likely to encounter therapeutically effective drug concentrations, thereby further promoting resistance. Understanding the dynamic interactions between tumor cells and their microenvironment is therefore essential for the development of therapeutic strategies capable of overcoming this form of resistance (Figure 1).

Figure 1.

Cancer resistance mechanisms.

TME, tumor microenvironment; TAM, tumor-associated macrophages.

Biotechnological Solutions to Overcome Cancer Drug Resistance

Genetic Engineering and CRISPR Technology

Genetic engineering using CRISPR/Cas9 technology offers promising opportunities to overcome cancer drug resistance. CRISPR/Cas9 enables precise genome editing, allowing targeted modification of specific genes that contribute to resistance mechanisms [32]. This technology can be used to knock out genes responsible for cancer drug efflux, such as P-glycoprotein, thereby increasing tumor cell susceptibility to chemotherapy [33]. In addition, CRISPR can be applied to correct mutations that drive resistance to targeted therapies, restoring the effectiveness of drugs that were previously ineffective [34,35]. Beyond direct targeting of resistance-related genes, CRISPR technology can also be used to engineer immune cells, such as T cells, to enhance their capacity to recognize and eliminate cancer cells [36].

Gene-editing platforms such as CRISPR/Cas9 provide a highly precise approach to counteracting the genetic determinants of drug resistance. Resistance frequently arises from mutations that alter drug-binding sites, upregulate efflux transporters, or disrupt apoptotic pathways [5]. CRISPR-mediated knockout of efflux pump genes, such as ABCB1 encoding P-glycoprotein, and correction of resistance-associated driver mutations have demonstrated potential to restore chemosensitivity [37]. Furthermore, CRISPR-based approaches can reprogram immune cells, thereby enhancing T-cell recognition of tumor antigens and reducing immune evasion [38]. Although CRISPR-based therapeutics have advanced into early-phase clinical trials for hematologic disorders, their application to cancer drug resistance remains largely preclinical [34]. Ongoing clinical studies are evaluating CRISPR-edited T cells in solid tumors, with preliminary safety and efficacy data suggesting feasibility [39]. However, regulatory approval remains constrained by concerns related to off-target effects, delivery efficiency, and long-term genomic stability [40]. At present, genetic engineering and CRISPR-based technologies are largely confined to high-income settings with well-developed genomic and regulatory infrastructure [41]. In low- and middle-income countries (LMICs), limited sequencing capacity, insufficient ethical oversight, and substantial cost barriers restrict clinical translation [42]. Broad implementation will require targeted capacity-building initiatives, subsidized gene-editing platforms, and harmonized regulatory frameworks to ensure safety and equitable access.

Targeted Therapy and Next-Generation Drug Development

Biotechnology has enabled the development of next-generation targeted therapies that directly address the molecular drivers of cancer drug resistance. These therapies are designed to inhibit specific proteins or signaling pathways altered in cancer cells, thereby reducing reliance on conventional cytotoxic chemotherapy. Novel inhibitors targeting mutant forms of proteins such as EGFR or BRAF have demonstrated promise in overcoming resistance in selected cancer types [43]. These agents are engineered to bind more effectively to mutated targets, thereby counteracting resistance-conferring alterations that would otherwise reduce drug efficacy [44]. In addition to single-agent approaches, combination therapies incorporating multiple targeted drugs are being developed to address the complex and multifactorial nature of resistance [43]. By simultaneously targeting distinct pathways or resistance mechanisms, combination strategies may overcome adaptive cellular responses that emerge during treatment [45]. Combining targeted therapies with immunotherapies or epigenetic drugs may provide a more comprehensive approach to overcoming resistance. Next-generation targeted therapies specifically address molecular events underlying acquired resistance to first-line inhibitors. Key mechanisms include mutations within kinase domains and activation of alternative signaling pathways that compensate for inhibited targets [46]. Newer inhibitors are designed to exhibit higher binding affinity and broader mutation coverage, while combination regimens aim to suppress compensatory signaling networks [5]. Several next-generation inhibitors have received regulatory approval from agencies such as the US Food and Drug Administration and European Medicines Agency for the treatment of resistant malignancies. In parallel, numerous phase II and III clinical trials are evaluating dual- or multi-targeted regimens, including combination strategies that integrate immunotherapies [47]. The effectiveness of targeted therapy is also influenced by regional patterns of genomic variation. For instance, EGFR mutations occur at higher frequencies in East Asian populations, shaping treatment selection and adoption [48]. However, in regions lacking access to molecular diagnostic testing, the benefits of precision-targeted therapy remain limited. High drug costs, inadequate reimbursement mechanisms, and insufficient diagnostic infrastructure in LMICs continue to pose major barriers to equitable implementation [49].

Computational Aspects in Drug Development

Computational technologies are becoming increasingly essential for the development of therapies aimed at overcoming cancer drug resistance, effectively bridging the gap between laboratory research and clinical application. Approaches such as molecular dynamics simulations, machine learning algorithms, and structure-based drug design are transforming how next-generation therapies are identified and optimized [50,51]. These computational methods enable prediction of how mutations in key cancer-related proteins influence drug binding and activity, thereby facilitating the design of more effective and selective inhibitors [52,53]. Virtual screening tools, which assess interactions between thousands of small molecules and mutated protein targets, further accelerate the identification of candidate compounds capable of bypassing known resistance mechanisms [54]. Beyond drug design, computational approaches also support the development of combination therapies. By integrating genomic, proteomic, and transcriptomic datasets, computational models assist in identifying synergistic drug combinations that simultaneously target multiple resistance pathways [55,56]. These models additionally enable personalized selection of combination regimens tailored to an individual patient’s molecular profile. Furthermore, artificial intelligence (AI) and machine learning techniques are increasingly applied to large-scale datasets to predict patterns of drug resistance, treatment responses, and the emergence of novel mutations [57,58]. This predictive capacity is particularly important for designing adaptive treatment strategies and improving clinical outcomes. As computational tools continue to advance, they are expected not only to accelerate drug discovery but also to enhance treatment precision by enabling timely identification of effective therapies and supporting long-term survival in cancer patients.

Nanotechnology in Drug Delivery

Nanotechnology offers a novel strategy for overcoming drug resistance by enhancing the delivery and effectiveness of chemotherapeutic and targeted agents. Nanoparticles, including liposomes and polymer-based carriers, can encapsulate drugs and deliver them directly to tumor sites, thereby overcoming barriers that limit effective drug penetration [59]. This targeted delivery approach increases the local concentration of therapeutic agents within tumors while reducing systemic toxicity. In addition to improving delivery efficiency, nanoparticles can be engineered to respond to specific conditions within the TME [60]. For example, nanoparticles may be designed to release their drug payloads in response to stimuli such as pH or temperature changes, which are commonly observed in tumor tissues [61,62]. Nanomedicine can also address MDR by co-encapsulating multiple agents within a single nanoparticle, enabling combination therapy while reducing the likelihood of drug efflux from cancer cells [63].

Nanocarrier-based delivery systems help mitigate pharmacokinetic barriers that contribute to drug resistance. Encapsulation within nanoparticles can bypass efflux pumps, enhance tumor accumulation through the enhanced permeability and retention effect, and enable localized drug release in response to tumor-specific stimuli [64]. These mechanisms collectively increase intracellular drug concentrations while limiting systemic toxicity. Several nanomedicines, including liposomal doxorubicin and albumin-bound paclitaxel, have received clinical approval [65]. At the same time, newer multifunctional nanoparticle platforms are progressing through early-stage clinical trials. Despite their promising therapeutic potential, challenges related to scalability, manufacturing reproducibility, and long-term toxicity continue to present significant regulatory hurdles [66].

Translation of nanotechnology-based therapies into routine clinical practice depends on the availability of advanced manufacturing processes and robust quality-control systems. High production costs and limited regulatory expertise in nanomedicine oversight restrict accessibility, particularly in LMICs [67]. Regional collaborations and technology-transfer initiatives are therefore critical for supporting local manufacturing capacity and reducing reliance on imported nanomedicine formulations [68].

Immunotherapy and Biotechnology

Immunotherapy has emerged as one of the most promising treatment strategies for cancer, and biotechnology plays a critical role in developing and optimizing these therapies. Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, have revolutionized the treatment of cancers like melanoma and non-small cell lung cancer by blocking the immune checkpoints that cancer cells use to evade immune detection [69]. This enhances the immune system's ability to fight cancer cells. In addition to checkpoint inhibitors, chimeric antigen receptor T-cell (CAR-T) therapy is another breakthrough immunotherapy that has shown promise in treating certain hematologic cancers [70]. CAR-T cells are genetically engineered to target specific antigens on cancer cells, allowing for a more targeted and potent immune response [71].

Immunotherapeutic strategies specifically address resistance driven by immune escape mechanisms, including checkpoint activation, antigen loss, and an immunosuppressive TME [72]. Advances in biotechnology have optimized immune checkpoint inhibitors and enabled the development of genetically modified immune cells, such as CAR-T and T-cell receptor–engineered T cells, which enhance immune recognition and persistence [73]. Immune checkpoint inhibitors are now considered standard of care for melanoma, lung, and renal cancers, and numerous ongoing clinical trials are evaluating combination regimens to overcome acquired resistance [74]. CAR-T therapies have received regulatory approval for refractory hematologic malignancies; however, their efficacy in solid tumors remains an active area of investigation [75]. Biotechnology-driven innovations, including armored and logic-gated CAR-T constructs, are currently entering early-phase clinical trials [76].

The uptake of immunotherapy varies substantially due to differences in cost, infrastructure requirements, and availability of specialized clinical expertise [77]. CAR-T therapy remains largely inaccessible outside highly specialized centers in high-income settings, while LMICs face additional challenges related to limited cell-manufacturing facilities, inadequate reimbursement mechanisms, and underdeveloped ethical governance frameworks for advanced biologic therapies [78]. Expanding global access will depend on the development of decentralized manufacturing strategies and lower-cost biosimilar products (Figure 2; Table 1) [79–85].

Figure 2.

Immunotherapy & biotechnology platforms.

PD1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; CAR-T, chimeric antigen receptor T-cell.

Table 1.

Biotechnology platforms, clinical trial information, and key resistance mechanisms targeted in cancer treatment

Biotechnology platform	Clinical trial IDs	Tumor types	Key resistance mechanisms targeted
CRISPR/Cas9	NCT03745326, NCT02349633	Leukemia, solid tumors	Mutant EGFR, BCR-ABL, P-glycoprotein, apoptosis evasion [80]
CAR-T cell therapy	NCT02228096, NCT05253495	Leukemia, lymphomas, solid tumors	CD19+ resistance, immune checkpoint evasion, antigen loss [81,82]
Checkpoint Blockade (e.g., PD-1/PD-L1)	NCT02759783, NCT02819337	Melanoma, NSCLC, RCC	PD-L1 upregulation, immune evasion, tumor-associated macrophages [83,84]
Epigenetic modulators	NCT03522361	Solid tumors	DNA methylation, histone modifications, drug resistance gene reprogramming [85]

EGFR, epidermal growth factor receptor; CAR-T, chimeric antigen receptor T-cell; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma.

Public Health Challenges and Implications

Economic Costs of Drug Resistance

The economic burden associated with cancer drug resistance is substantial. The development of new therapies, particularly biologics and personalized treatments, is highly costly, and these therapies are often inaccessible to many patients because of their price. The reported cost to develop a cancer drug is approximately 648.0 million United States dollars (USD), which is significantly lower than some prior estimates but remains considerable [86]. Cancer drugs are frequently priced at more than 100,000 USD per year of treatment, with some approaching or exceeding 200,000 USD annually [86,87]. In addition, patients who develop resistance to an initial therapy may be required to transition to more expensive second- or later-line treatments, further increasing overall healthcare expenditures. These financial burdens are borne not only by healthcare systems but also by patients and their families, who may face substantial out-of-pocket costs for advanced therapies. The escalating economic impact of drug resistance underscores the need for more effective strategies to prevent and manage resistance, including the development of affordable treatment options and improved access to innovative therapies in low-resource settings.

Access to Biotechnology Solutions

Access represents one of the most significant challenges associated with biotechnology-based approaches to cancer drug resistance. Advanced interventions, including gene editing, nanomedicine, and immunotherapy, are frequently costly, limiting their availability primarily to well-resourced healthcare systems in high-income countries [86,87]. In low- and middle-income settings, constraints such as limited healthcare infrastructure, regulatory complexity, and financial barriers further exacerbate inequities in access to life-saving cancer treatments. Addressing these disparities will require coordinated efforts to ensure that biotechnological innovations are accessible across diverse populations, particularly in underserved regions. Public–private partnerships, sustained government investment, and international collaborations will be critical for reducing access gaps and promoting equitable distribution of advanced cancer therapies (Figure 3).

Figure 3.

Barriers and policy actions to expand access to biotechnological solutions for drug-resistant cancers.

Health Equity and Ethical Concerns

The rapid advancement of biotechnology raises important ethical questions related to equity, fairness, and access to emerging cancer treatments. As biotechnological innovation accelerates, concerns regarding unequal access to potentially life-saving therapies have intensified. Ethical considerations surrounding gene editing and personalized medicine, including issues related to safety and long-term consequences, require careful and ongoing evaluation. The use of CRISPR-Cas9 to genetically modify human germline cells and embryos, referred to as germline genome editing, remains particularly controversial. Germline genome editing presents multiple bioethical challenges, including the risk of unintended genetic alterations, uncertainty regarding informed consent, and the potential for eugenic practices through human selection [88]. Ensuring that technological advances benefit all populations necessitates the development of clear ethical guidelines, robust regulatory frameworks, and public policies that explicitly prioritize health equity (Table 2) [89–103].

Table 2.

Geographic trends in cancer drug resistance, access barriers, and feasibility of biotechnology implementation by region

Region	Geographic trends in cancer drug resistance	Access barriers	Feasibility of biotechnology implementation
Africa	Resistance in cancers such as cervical, breast, and prostate cancers. Multidrug resistance is commonly seen in chemotherapy for various cancers [89].	Severe healthcare infrastructure deficits, cost barriers, and a lack of specialized cancer care centers [90].	Low feasibility due to significant gaps in healthcare infrastructure, limited access to modern cancer treatments, and regulatory challenges [91].
Europe	Increasing resistance in breast cancer, colorectal cancer, and non-small cell lung cancer [92]	High costs of advanced therapies, with disparities in healthcare access between Western and Eastern Europe [93].	High feasibility in Western Europe with advanced healthcare systems, although cost and access disparities remain in Eastern Europe [94]
Asia	High prevalence of mutations in the epidermal growth factor receptor in lung cancer, particularly in East Asia. Resistance is also rising in gastrointestinal cancers and breast cancers [95].	Limited diagnostic capacity, affordability issues, and regulatory variability between countries [96].	Growing biotechnology sector in countries like China, Japan, and South Korea; significant access challenges in rural areas and for low-income populations [97].
North America	Resistance to common cancer therapies, such as epidermal growth factor receptor inhibitors in non-small cell lung cancer, and chemotherapy resistance in breast and prostate cancers [98].	High costs for biologic therapies, disparities in insurance coverage, and regulatory delays [99].	High feasibility due to strong biotechnology infrastructure and access to cutting-edge therapies, although high costs limit equitable access for certain populations [99,100].
South America	Increasing resistance in lung cancers [101].	Disparities in healthcare access between urban and rural areas, with high costs for advanced cancer treatments [102].	Moderate feasibility; adoption of biotechnology is increasing in urban centers, but rural and low-income areas face significant barriers to access [102,103].

Discussion

The future of biotechnology in cancer treatment depends on the continued development and integration of novel technologies capable of overcoming drug resistance. Emerging tools, including synthetic biology, AI-driven drug discovery, and advanced imaging techniques, are expected to further enhance the identification of new therapies and improve the precision of cancer treatment. With increasing computational power, these technologies can propose optimized drug combinations or personalized treatment strategies designed to overcome resistance and improve patient outcomes. For example, AI has been shown to optimize chemotherapy by integrating genetic mutation profiles, drug metabolism data, and drug sensitivity patterns to predict which patients are most likely to develop resistance, thereby enabling earlier and more targeted interventions [104]. Deep learning frameworks have also demonstrated the ability to process real-time imaging and biomarker data to identify early indicators of emerging resistance [104]. Similarly, AI has played an important role in advancing immunotherapy by analyzing tumor immune-evasion mechanisms to identify patients most likely to benefit from immune-based treatments, supporting the development of more targeted and effective personalized immunotherapies [104].

Despite their considerable promise, AI-driven approaches to drug discovery and treatment optimization raise important concerns related to health equity. The computational infrastructure and large, high-quality datasets required to train robust AI models are disproportionately concentrated in high-income countries [105–107]. As a result, the early benefits of AI-enabled drug development may accrue primarily to well-resourced settings. This creates a short-term paradox in which AI has the potential to reduce future drug development costs while simultaneously widening global access gaps in the near term (Figure 4).

Figure 4.

Applications of artificial intelligence (AI) in cancer drug resistance.

International collaboration will be essential for advancing biotechnology and addressing cancer drug resistance on a global scale. Multi-institutional partnerships, international clinical trial networks, and open-source data-sharing initiatives can accelerate the development of new therapies and help ensure that their benefits extend to patients worldwide. Global cooperation is also critical for addressing disparities in access to advanced treatments, particularly in low-resource settings that bear a disproportionate burden of drug-resistant cancers. At the same time, the rapid pace of biotechnological innovation requires regulatory agencies to adapt to novel scientific and clinical challenges. Clear, efficient, and harmonized regulatory pathways will be necessary to facilitate timely approval of new therapies. Governments and international organizations must therefore collaborate to address the ethical, legal, and financial complexities associated with implementing biotechnology-based cancer treatments.

Conclusion

Cancer drug resistance remains one of the most significant challenges in oncology; however, as demonstrated in this review, biotechnology offers promising strategies to address this persistent problem. Through the development of novel therapeutics, personalized medicine approaches, and advanced drug-delivery systems, biotechnology has the potential to fundamentally transform cancer treatment. Nonetheless, effectively addressing public health challenges related to high treatment costs, limited access, and ethical considerations is essential to ensure that the benefits of these innovations reach all populations, particularly those in low-resource settings. Continued research, international collaboration, and policy innovation will be critical to realizing the full potential of biotechnology in combating cancer drug resistance and improving global public health outcomes. Ensuring affordability and accessibility remains central to reducing disparities in cancer care. Moreover, targeted efforts to expand access in underserved regions are necessary to prevent the widening of existing health inequities. Without deliberate policy interventions and sustained global cooperation, biotechnological advances risk reinforcing disparities in cancer treatment and limiting their overall public health impact.

HIGHLIGHTS

• Emerging technologies such as synthetic biology, artificial intelligence, and advanced imaging have become increasingly necessary to overcome cancer drug resistance and to personalize treatment strategies.

• The growing economic burden of drug resistance underscores the need for more affordable therapies and improved access in low-resource settings. Global research collaboration and efficient regulatory pathways are essential to ensure equitable access to innovative treatments.